Total: $764.71M

Company
(Symbol)#
(M)

Type Of
Financing

Number Of Shares, Units
Or Warrants

Amount Raised (M)

Investors; Placement Agents; Details (Date)@


Allon
Therapeutics
Inc.
(Canada;
CDNX:NPC)

Private placement of stock

6S

C$6.3 (US$5.3)

The shares were sold at C$1.05 each; as part of the deal about 2.5M previously issued warrants were redeemed for C$0.05 each (8/29)

AMDL Inc.
(AMEX:ADL)

Private placement of stock and warrants

3.164S and 1.9W

$1

The financing had two closings; shares were sold at $0.32 and $0.315 each; the three-year warrants are exercisable at $0.49 and $0.48 per share; Galileo Asset Management SA and Havkit Corp. were placement agents (8/18 and 8/30)

Astralis Ltd.
(OTC BB:ASTR)

Private placement of stock and warrants

18.18S and ND

$2

Blue Cedar Ltd. purchased the shares at $0.11 each; warrant terms were not disclosed; a second closing in the round was expected in September (8/19)

Biotech
Holdings Ltd.
(Canada; OTC BB:
BIOHF)

Private placement of stock

0.419S and 0.419W

C$0.12 (US$0.1)

A company insider purchased the shares at C$0.29 each; the warrants are exercisable at C$0.39 each (8/10)

Boston Life
Sciences Inc.
(BLSI)

Private placement of stock

6S

$12.78

The shares were sold at $2.13 each; Robert L. Gipson was expected to own 19.9% of the company following the stock sale (8/30)

Callisto
Pharmaceuticals
Inc.
(AMEX:KAL)

Private placement of stock

1.87S

$1.81

Existing shareholders purchased the stock at $0.97 per share (8/23)

Coley
Pharmaceutical
Group Inc.
(COLY)

Private placement of stock

0.625S

$10

Pfizer Inc. purchased the shares privately in a deal concurrent with the company's initial public offering; the shares were purchased at the $16 IPO price (8/10)

Genta Inc.
(GNTA)

Private placement of stock

19.1S

$17.5

The shares were sold from an existing registration statement; Piper Jaffray & Co. was placement agent (8/8)

GTC
Biotherapeutics
Inc.
(GTCB)

Private placement of stock and warrants

4.57S and 1.8W

$8

The shares were sold at $1.75 each; the five-year warrants are exercisable at $2.68 per share; Rodman & Renshaw LLC was placement agent (8/8)

Human Genome
Sciences Inc.
(HGSI)

Private placement of convertible notes

N/A

$230

The 2.25% subordinated notes due 2012 are convertible into common stock at $17.78 per share (8/4)

International
Medical
Innovations
Inc.
(Canada;
TSE:IMI)

Bought-deal placement of units

N/A

C$10 (US$8.4)

Each unit comprised a $1,000 principal amount 7% convertible debentures and 157 common-share purchase warrants; each four-year warrant is convertible into common stock at $2.85 per share (8/18)

Inhibitex Inc.
(INHX)

Private placement of stock

5S

$41.25

Institutional investors purchased the shares at $8.25 each; Lazard Capital Markets LLC was placement agent (8/18)

InNexus
Biotechnology
Inc.
(Canada;
OTC BB:ISXBF)

Private placement of securities

N/A

$3.05

The company raised $2.5M through the sale of 8% to 12% notes convertible into 10M shares and 10M $0.25 warrants; it also got a $0.25M bridge loan, and it raised $0.3M through the placement of 1.2M shares and 1.2M $0.30 warrants (8/8)

Isis
Pharmaceuticals
Inc.
(ISIS)

Private placement of stock and warrants

12S and 3W

$51

The shares were sold at $4.25 each, and the warrants are exercisable at $5.23 per share; Needham & Co. and Fortis Securities LLC were placement agents (8/22)

Kamada Ltd.
(Israel; TEL:KMDA)

Initial offering of stock

1.875S

NIS30 (US$6.7)

Kamada completed an initial public offering on the Tel Aviv Stock Exchange; the offering was underwritten by Poalim IBI, Clal Finance Underwriting, Altshouler-Shacham and Rosario Capital (8/17)

Large Scale
Biology Corp.
(LSBC)

Bridge loan

N/A

$1

Two company officials provided $1M in a term-loan deal, which also included the issuance of warrants; separately, it entered a deal under which it can sell $15M in stock to Brittany Capital over three years (8/8)

Manhattan
Pharmaceuticals
Inc.
(OTC BB: MHTT)

Private placement of stock and warrants

10.76S and 2.15W

$11.9

The shares were sold at $1.11 each; the five-year warrants are exercisable at $1.44 per share; Paramount BioCapital Inc. was placement agent (8/30)

MannKind
Corp.
(MNKD)

Private placement of stock and warrants

17.1S and 3.4W

$175

Half the money was invested by institutional investors and half by MannKind Chairman and CEO Alfred Mann; the warrants are exercisable at $12.228 per share; Wachovia Securities and Leerink Swann & Co. were placement agents (8/3)

Medicure Inc.
(Canada; TSE:
MPH)

Private placement of stock and warrants

5.21S and 2.6W

$3.85

The shares were sold at $0.74 each; the five-year warrants are exercisable at $0.97 per share; Satellite Asset Management LP led the placement; Needham & Co. was placement agent (8/22)

MIV
Therapeutics
Inc.
(Canada;
OTC BB:MIVT)

Private placement of securities

ND

$4.14

Details on the non-brokered private placement were not disclosed (8/22)

Nektar
Therapeutics
(NKTR)

Private placement of stock and warrants

1.436S and 0.45W

$24

The shares were sold from a shelf registration at $16.71 to Mainfield Enterprises Inc., which also got a 15-month option to purchase additional shares (8/16)

Nutra Pharma
Corp.
(OTC BB:
NPHC)

Private placement of stock and warrants

24S and 6W

$9.6

SBI Brightline XII LLC is obligated to buy, upon Nutra Pharma's election, up to 24M shares of common stock; the warrants are exercisable from $0.30 to $0.50 per share (8/18)

Peplin Ltd.
(Australia; ASX:
PEP)

Private placement of stock

11.4S

A$4 (US$3.1)

Shares in the placement were sold at A$0.35 each; shareholders also received the right to purchase shares at that price through Aug. 26 (8/2)

pSivida Ltd.
(Australia; PSDV)

Private placement of stock and warrants

6.5S and 0.65W

$4.23

The company sold 650,000 American depository receipts at $6.50 each; each ADR represents 10 ordinary shares; the 3-year warrants are exercisable at $12.50 per ADR (8/24)

Regeneration
Technologies
Inc.
(RTIX)

Private placement of stock

2.8S

$23.9

The shares were sold at $8.55 each; Pacific Growth Equities LLC was placement agent (8/29)

ReNeuron
Group plc
(UK; AIM:RENE)

Private placement of stock and warrants

38S and 19W

£9.5 (US$17.2)

ReNeuron gained a listing on AIM along with the placement in the UK and U.S.; shares were sold at 25 pence each; the warrants are exercisable at 30 pence each; Collins Stewart and Harris Nesbitt Corp. were agents in the deal (8/5)

Rexahn
Pharmaceuticals
Inc.
(OTC BB:
RXHN)

Private placement of convertible notes and stock

N/A and 4.175S

$9.65

The three-year notes are convertible into common stock at $2 per share; the shares were sold at $2 each (8/11)

Santarus Inc.
(SNTS)

Private placement of stock

7.35S

$31.2

The shares were sold from a shelf registration at $4.25 each; SG Cowen & Co. LLC was lead placement agent and RBC Capital Markets Corp. was co-placement agent (8/17)

Sonus
Pharmaceuticals
Inc.
(SNUS)

Private placement of stock and warrants

4.65S and 2.33W

$16.8

Shares were purchased at $3.77 each; for another $0.125 per underlying share, investors also got five-year warrants exercisable at $4.15 per share; investors included Domain Public Equity Partners, Efficacy Capital, MPM BioEquities, ProMed and Heights Capital Management; Punk Ziegel & Co. was placement agent (8/16)

Vaso Active
Pharmaceuticals
Inc.
(PK:VAPH)

Private placement of convertible notes and warrants

N/A and 1.3W

$2.5

The $2.5M in notes due May 2007 are convertible into stock at $0.70 per share; the five- year warrants are exercisable at $0.77 per share; investors also have a right to purchase another $1.88M in notes and 974,026 warrants (8/16)

Viventia
Biotech Inc.
(Canada; TSE:VBI)

Bridge loans

N/A

C$3.3 (US$2.75)

Viventia Chairman Leslie Dan provided loans totaling C$3.3; they carry a 4.5% annual interest rate (8/12)

Vyteris
Holdings Inc.
(OTC BB:VYHN)

Private placement of convertible notes and warrants

N/A and 2.08W

$10

The three-year, 8% notes are convertible into common stock at $2.40 per share; the warrants are exercisable at $2.88 per share; investors have an option to invest another $5M on those terms (8/19)

Xenogen
Corp.
(XGEN)

Private placement of stock and warrants

5.155S and 1.55W

$15

The shares were sold at $2.91 each and the warrants are exercisable at $3.29 per share; Thomas Weisel Partners LLC was placement agent (8/11)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Market Index; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TEL = Tel Aviv Stock Exchange; TSE = Toronto Stock Exchange.

No Comments